A Cancer Driven by Ultra-Rare Mutation Gets Its First FDA-Approved Therapy

May 11, 2026
, 7:44 pm

A VPN is an essential component of IT security, whether you’re just starting a business or are already up and running. Most business interactions and transactions happen online and VPN

Partner Therapeutics’ Bizengri is now FDA approved for treating advanced cases of cholangiocarcinoma driven by NRG1 gene fusions. Partner acquired U.S. rights to this bispecific antibody from Merus in 2024.

The post A Cancer Driven by Ultra-Rare Mutation Gets Its First FDA-Approved Therapy appeared first on MedCity News.

Leave a Replay

This Startup Aims to Upend Biologic Drug Production With Implantable ‘Cell Factories’

Could Cigna Exiting the Individual Market be an Indictment of ICHRA?

What Can Providers Do Differently to Get Paid Sooner?

Sign up for our Newsletter

HealthGility provides healthcare organizations with a solution for patient protected health information disclosure and confidentiality that reduces workloads and ensures the safe and secure sharing of sensitive data between different providers.

A Cancer Driven by Ultra-Rare Mutation Gets Its First FDA-Approved Therapy

Leave a Replay

Related Posts

This Startup Aims to Upend Biologic Drug Production With Implantable ‘Cell Factories’

Could Cigna Exiting the Individual Market be an Indictment of ICHRA?

What Can Providers Do Differently to Get Paid Sooner?

Follow Us

Sign up for our Newsletter

Our Company

Resources

Connect

© All rights reserved

Contact Us